CIA Director William Burns tests positive for Covid after meeting with Biden, but is not considered a close contact

CIA Director William Burns tests positive for Covid after meeting with Biden, but is not considered a close contact


CIA Director Bill Burns testifies next to Director of National Intelligence Avril Haines during a House (Select) Intelligence Committee hearing on diversity in the intelligence community, on Capitol Hill in Washington, October 27, 2021.

Elizabeth Frantz | Reuters

WASHINGTON – CIA Director William Burns tested positive for Covid-19 on Thursday, the intelligence agency said.

Burns, who is fully vaccinated and boosted against Covid-19, last met with President Joe Biden on Wednesday morning during a “socially distanced meeting and was wearing an N-95 mask.”

“Their interaction is not considered close contact as defined by CDC guidance, and Director Burns is sharing the news of his positive test out of an abundance of transparency,” the intelligence agency wrote in a statement.

Burns will continue to perform his duties as CIA director but will work from home. He will return to the office following a negative test and after isolating for five days. The agency said that Burns has experienced mild symptoms.

Burns’ positive test follows two other virus cases within Biden’s orbit.

On Sunday, White House deputy press secretary Karine Jean-Pierre said she tested positive for Covid-19. Her positive test result came several days after White House press secretary Jen Psaki tested positive for the virus, which prevented her from traveling with Biden to Belgium and Poland.

Psaki said at the time that Biden was not considered a close contact following two socially distanced meetings.

Earlier this month, second gentleman Doug Emhoff tested positive for Covid-19. Following the positive test result, the White House said that Vice President Kamala Harris would skip a scheduled event “out of an abundance of caution.”

Biden, 79, received his fourth dose of the coronavirus vaccine on Wednesday.



Source

Healthy Returns: Chinese obesity drug emerges as a potential rival to Eli Lilly’s Zepbound
Health

Healthy Returns: Chinese obesity drug emerges as a potential rival to Eli Lilly’s Zepbound

Cr | Istock | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Another potential competitor to blockbuster obesity treatments from Eli Lilly and Novo Nordisk just showed positive data – but this time, […]

Read More
FDA to consider drug affordability when granting new vouchers to speed up approvals, Makary says
Health

FDA to consider drug affordability when granting new vouchers to speed up approvals, Makary says

The Food and Drug Administration will consider drug affordability when granting companies new vouchers that speed up approvals of some treatments, the agency’s Commissioner Marty Makary told CNBC on Friday.  The FDA in June announced a national priority voucher plan that aims to cut drug review times to one-to-two months for companies it says are […]

Read More
Hims & Hers to offer generic semaglutide in Canada as Novo Nordisk patent lapses
Health

Hims & Hers to offer generic semaglutide in Canada as Novo Nordisk patent lapses

The Hers website arranged on a laptop in New York, US, on Wednesday, Feb. 12, 2025. Gabby Jones | Bloomberg | Getty Images Hims & Hers Health announced Wednesday it will offer generic semaglutide in Canada as Novo Nordisk‘s patent on its branded drugs Ozempic and Wegovy is set to expire in January. “Canada is […]

Read More